INT136180

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2003
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 5.01
Pain Relevance 0.38

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MTOR) Golgi apparatus (MTOR) endoplasmic reticulum (MTOR)
cytoplasm (MTOR) cytosol (MTOR) signal transduction (MTOR)
Anatomy Link Frequency
blood 1
MTOR (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 9 96.94 Very High Very High Very High
rheumatoid arthritis 5 96.80 Very High Very High Very High
Inflammation 12 91.80 High High
tolerance 3 84.08 Quite High
Arthritis 3 78.36 Quite High
Multiple sclerosis 1 75.28 Quite High
anakinra 1 29.92 Quite Low
palliative 1 29.84 Quite Low
Infliximab 1 22.52 Low Low
imagery 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Tuberous Sclerosis 4 99.16 Very High Very High Very High
Graft Vs Host Disease 1 99.08 Very High Very High Very High
Systemic Lupus Erythematosus 56 99.04 Very High Very High Very High
Metabolic Syndrome 52 97.80 Very High Very High Very High
Carcinoma 16 96.96 Very High Very High Very High
Rheumatoid Arthritis 6 96.80 Very High Very High Very High
Renal Cell Carcinoma 116 95.80 Very High Very High Very High
INFLAMMATION 12 91.80 High High
Cancer 84 90.44 High High
Leukemia 3 87.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Activated AKT phosphorylates and inhibits tuberous sclerosis complex (TSC) and removes its inhibitory effect on mTOR.18,19
mTOR Binding (effect) of associated with tuberous sclerosis
1) Confidence 0.35 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.70 Pain Relevance 0
The everolimus-FKBP12 complex binds to mTOR and reduces the activity of the downstream effectors S6 ribosomal protein kinase (S6K1) and translational repressor protein eukaryotic elongation factor 4E-binding protein (4EBP).19 eIF-4F activation results in the translation of a subset of capped mRNA containing highly structured 5?
mTOR Binding (binds) of
2) Confidence 0.35 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.36 Pain Relevance 0
mTOR exists in two complexes called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), that differ in subunit composition and sensitivity to rapamycin.20 mTORC1 is highly sensitive to rapamycin whereas mTORC2 is relatively insensitive to rapamycin.21 HIF-1?
mTOR Binding (complexes) of
3) Confidence 0.35 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.65 Pain Relevance 0
Everolimus (Afinitor®; RAD001; Novartis, USA) is an orally bioavailable mTOR inhibitor that binds with high affinity to its intracellular receptor FKBP12, at the same point in the mTOR pathway as temosirolimus.
mTOR Binding (binds) of
4) Confidence 0.33 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.50 Pain Relevance 0
Indeed, cytokines such as TNF alpha - which are high in MetS-patient blood cause serine phosphorylation of IRS-1 and inhibit its tyrosine phosphorylation with consequent impairment of mTOR function [16].
mTOR Neg (impairment) Binding (impairment) of in blood associated with metabolic syndrome and cytokine
5) Confidence 0.33 Published 2010 Journal Cardiovasc Diabetol Section Body Doc Link PMC2940873 Disease Relevance 0.88 Pain Relevance 0.18
Sirolimus (rapamycin) binds the regulatory kinase mTOR and is used for renal transplant rejection prevention.
mTOR Binding (binds) of associated with graft vs host disease
6) Confidence 0.29 Published 2010 Journal BMC Med Section Body Doc Link PMC3009611 Disease Relevance 0.94 Pain Relevance 0.21
No significant difference was observed between any treatment groups for mRNA expression for PKB, mTOR, p70S6k, GSK-3?
mTOR Binding (p70S6k) of
7) Confidence 0.17 Published 2008 Journal American Journal of Physiology - Endocrinology and Metabolism Section Body Doc Link PMC2536736 Disease Relevance 0 Pain Relevance 0
Calibration was performed with a FRAP reagent containing the addition of FeCl2 (total sample volume 1.02 ml, final concentrations from 20 to 2000 ?
FRAP Binding (reagent) of
8) Confidence 0.13 Published 2008 Journal J Negat Results Biomed Section Body Doc Link PMC2607253 Disease Relevance 0.07 Pain Relevance 0
It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates.
target kinase Binding (binds) of
9) Confidence 0.01 Published 2003 Journal J. Exp. Clin. Cancer Res. Section Abstract Doc Link 16767900 Disease Relevance 0.91 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox